KR102104144B1 - 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도 - Google Patents
3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도 Download PDFInfo
- Publication number
- KR102104144B1 KR102104144B1 KR1020147026143A KR20147026143A KR102104144B1 KR 102104144 B1 KR102104144 B1 KR 102104144B1 KR 1020147026143 A KR1020147026143 A KR 1020147026143A KR 20147026143 A KR20147026143 A KR 20147026143A KR 102104144 B1 KR102104144 B1 KR 102104144B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- independently
- compound
- present
- nhr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C/N=C(\S(=C)=*C(N)=*)/[Zn] Chemical compound C/N=C(\S(=C)=*C(N)=*)/[Zn] 0.000 description 5
- TVDHGNPNJJNZOO-UHFFFAOYSA-N CC(C)(C)[Si+](c1ccccc1)(c1ccccc1)OC(C1)CN1C(Cc(cc1)ccc1Br)=O Chemical compound CC(C)(C)[Si+](c1ccccc1)(c1ccccc1)OC(C1)CN1C(Cc(cc1)ccc1Br)=O TVDHGNPNJJNZOO-UHFFFAOYSA-N 0.000 description 1
- BLPHGAIBLWLNCX-UHFFFAOYSA-N CC(C)(c(cc1)ccc1Br)N(CC1)CCN1S(c1ccc(C)cc1)(=O)=O Chemical compound CC(C)(c(cc1)ccc1Br)N(CC1)CCN1S(c1ccc(C)cc1)(=O)=O BLPHGAIBLWLNCX-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N CN1CCNCCC1 Chemical compound CN1CCNCCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- ZVCKXYHLTIRKIQ-UHFFFAOYSA-N Cc1c(C=C(c2ccc(CN(C3)CC3O)cc2)NC2=O)c2cc(F)c1 Chemical compound Cc1c(C=C(c2ccc(CN(C3)CC3O)cc2)NC2=O)c2cc(F)c1 ZVCKXYHLTIRKIQ-UHFFFAOYSA-N 0.000 description 1
- HFVOJSDRWKEERW-UHFFFAOYSA-N Cc1cccc2c1C=C(B(O)O)NC2=O Chemical compound Cc1cccc2c1C=C(B(O)O)NC2=O HFVOJSDRWKEERW-UHFFFAOYSA-N 0.000 description 1
- KLAVXASCAJLSQX-UHFFFAOYSA-N Cc1cccc2c1C=C(c(cc1)ccc1C(N(C)CC1CCOCC1)=O)NC2=O Chemical compound Cc1cccc2c1C=C(c(cc1)ccc1C(N(C)CC1CCOCC1)=O)NC2=O KLAVXASCAJLSQX-UHFFFAOYSA-N 0.000 description 1
- QOOPQYLLXBKXQI-UHFFFAOYSA-N OB(c(c(F)c1)ccc1C(N1CCOCC1)=O)O Chemical compound OB(c(c(F)c1)ccc1C(N1CCOCC1)=O)O QOOPQYLLXBKXQI-UHFFFAOYSA-N 0.000 description 1
- SDCUFOPXAVOYBP-UHFFFAOYSA-N OCCN(CC1)CCN1C(c(cc1)ccc1C(NC(c1cc(F)c2)=O)=Cc1c2F)=O Chemical compound OCCN(CC1)CCN1C(c(cc1)ccc1C(NC(c1cc(F)c2)=O)=Cc1c2F)=O SDCUFOPXAVOYBP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607680P | 2012-03-07 | 2012-03-07 | |
| US61/607,680 | 2012-03-07 | ||
| PCT/GB2013/050561 WO2013132253A1 (en) | 2012-03-07 | 2013-03-07 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150001734A KR20150001734A (ko) | 2015-01-06 |
| KR102104144B1 true KR102104144B1 (ko) | 2020-04-23 |
Family
ID=47891779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147026143A Expired - Fee Related KR102104144B1 (ko) | 2012-03-07 | 2013-03-07 | 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9193689B2 (enExample) |
| EP (1) | EP2822656B1 (enExample) |
| JP (1) | JP6082409B2 (enExample) |
| KR (1) | KR102104144B1 (enExample) |
| CN (1) | CN104302358B (enExample) |
| AU (1) | AU2013229229B2 (enExample) |
| CA (1) | CA2865511A1 (enExample) |
| DK (1) | DK2822656T3 (enExample) |
| ES (1) | ES2611504T3 (enExample) |
| IN (1) | IN2014MN01875A (enExample) |
| MX (1) | MX346147B (enExample) |
| RU (1) | RU2696572C2 (enExample) |
| WO (1) | WO2013132253A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| CN104507912B (zh) * | 2012-08-08 | 2016-09-28 | 默克专利股份公司 | (氮杂-)异喹啉酮衍生物 |
| CA2922469A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| DK3356345T3 (da) * | 2015-09-30 | 2024-02-12 | Max Planck Gesellschaft | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer |
| CN108289448B (zh) | 2015-12-02 | 2021-10-22 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| UY37623A (es) | 2017-03-03 | 2018-09-28 | Syngenta Participations Ag | Derivados de oxadiazol tiofeno fungicidas |
| WO2018219773A1 (en) | 2017-06-02 | 2018-12-06 | Syngenta Participations Ag | Fungicidal compositions |
| CN110709395A (zh) | 2017-06-02 | 2020-01-17 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| US20200315176A1 (en) | 2017-06-28 | 2020-10-08 | Syngenta Participations Ag | Fungicidal compositions |
| BR112020000465B1 (pt) | 2017-07-11 | 2024-02-20 | Syngenta Participations Ag | Derivados oxadiazol microbiocidas |
| WO2019011929A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019011928A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019011926A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| BR112020000371A2 (pt) | 2017-07-12 | 2020-07-14 | Syngenta Participations Ag | derivados de oxadiazol microbiocidas |
| BR112020000463A2 (pt) | 2017-07-13 | 2020-07-21 | Syngenta Participations Ag | derivados oxadiazol microbiocidas |
| US12402885B2 (en) | 2017-09-23 | 2025-09-02 | Universität Zürich | Medical occlusion device |
| EP3459469A1 (en) | 2017-09-23 | 2019-03-27 | Universität Zürich | Medical occluder device |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| CN112689631A (zh) | 2018-07-16 | 2021-04-20 | 先正达农作物保护股份公司 | 杀微生物的噁二唑衍生物 |
| ES2960987T3 (es) | 2019-04-12 | 2024-03-07 | Riboscience Llc | Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1 |
| AR118673A1 (es) * | 2019-04-18 | 2021-10-20 | Syngenta Crop Protection Ag | Procedimiento para la preparación de derivados de oxadiazol microbiocidas |
| EP4033999B1 (en) | 2019-09-26 | 2024-11-27 | Universität Zürich | Left atrial appendage occlusion devices |
| JP7512380B2 (ja) * | 2019-10-30 | 2024-07-08 | ディグムバイオ．インコーポレイテッド | イソキノリノン誘導体、その製造方法及びそれを有効成分として含有するポリ（ａｄｐ－リボース）ポリメラーゼ－１（ｐａｒｐ－１）関連疾患の予防又は治療用薬学的組成物 |
| US12564408B2 (en) | 2020-03-25 | 2026-03-03 | Universitat Zurich | Medical occluder delivery systems |
| WO2022087269A1 (en) | 2020-10-21 | 2022-04-28 | Verint Americas Inc. | System and method of automated determination of use of sensitive information and corrective action for improper use |
| CN117043302A (zh) | 2021-03-18 | 2023-11-10 | 默克专利有限公司 | 用于有机电致发光器件的杂芳族化合物 |
| US20240246903A1 (en) * | 2021-05-04 | 2024-07-25 | Board Of Regents, The University Of Texas System | Indanone and tetraloneketo or hydroxyl oximes as cancel therapeutics |
| EP4359401A1 (en) * | 2021-06-23 | 2024-05-01 | Blueprint Medicines Corporation | Process for preparing egfr inhibitors |
| JP2025508714A (ja) * | 2022-02-16 | 2025-04-10 | デューク ストリート バイオ リミテッド | 医薬化合物 |
| CN115572262B (zh) * | 2022-10-27 | 2024-08-27 | 厦门沃克沃德医药科技有限公司 | 一种异喹啉衍生物及其制备方法 |
| WO2024238871A1 (en) * | 2023-05-18 | 2024-11-21 | Rectify Pharmaceuticals, Inc. | Aryl sulfonamide compounds and their use in treating medical conditions |
| GB2634228A (en) * | 2023-10-02 | 2025-04-09 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
| AU2024406047A1 (en) * | 2023-12-19 | 2026-07-16 | Merck Sharp & Dohme Llc | Agonists of trem2 activity |
| CN122079889B (zh) * | 2026-04-24 | 2026-08-07 | 北京海望氢能科技有限公司 | 异喹啉的合成方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049555A1 (en) | 2005-08-24 | 2007-03-01 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2851458A (en) | 1955-06-08 | 1958-09-09 | Burroughs Wellcome Co | Diquaternary compounds and the manufacture thereof |
| US3464563A (en) | 1967-02-06 | 1969-09-02 | American Air Filter Co | Liquid filter apparatus |
| US4678500A (en) | 1984-06-29 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US4942163A (en) | 1989-03-07 | 1990-07-17 | E. I. Du Pont De Nemours And Company | 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents |
| WO1999018077A1 (en) | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Fused pyridine derivatives |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20040176361A1 (en) | 2001-05-23 | 2004-09-09 | Masakazu Fujio | Fused heterocyclic compound and medicinal use thereof |
| AU2002341693B2 (en) | 2001-09-21 | 2008-05-29 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| AU2003255149A1 (en) * | 2002-07-24 | 2004-02-09 | Kyorin Pharmaceutical Co., Ltd. | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| CN100390164C (zh) * | 2002-10-01 | 2008-05-28 | 三菱制药株式会社 | 异喹啉化合物及其医药用途 |
| KR20050065624A (ko) | 2002-10-23 | 2005-06-29 | 그렌마크 파머수티칼스 엘티디. | 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물 |
| WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
| ATE422895T1 (de) | 2003-04-16 | 2009-03-15 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| WO2005075432A1 (ja) | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用 |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| WO2005113540A1 (ja) | 2004-05-20 | 2005-12-01 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| US7846915B2 (en) | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| CN101437514B (zh) | 2004-10-22 | 2012-04-25 | 詹森药业有限公司 | C-fms激酶抑制剂 |
| ATE412636T1 (de) | 2004-12-16 | 2008-11-15 | Hoffmann La Roche | Piperazinylpyridinderivate als mittel gegen adipositas |
| TWI389897B (zh) | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
| SI1864976T1 (sl) | 2005-03-31 | 2012-12-31 | Astellas Pharma Inc. | Propan-1,3-dionski derivat ali njegova sol |
| WO2007016525A2 (en) | 2005-07-29 | 2007-02-08 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| CA2662112A1 (en) | 2006-09-05 | 2008-03-13 | Kyowa Hakko Kirin Co., Ltd. | Imidazole derivatives and their use as cannabinoid type 2 (cb2) receptor modulators |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| FR2919286A1 (fr) * | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| US20090054392A1 (en) | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| WO2009027650A1 (en) | 2007-08-24 | 2009-03-05 | The Institute Of Cancer: Royal Cancer Hospital | Materials and methods for exploiting synthetic lethality in brca-associated cancers |
| AU2008324203A1 (en) | 2007-11-05 | 2009-05-14 | Novartis Ag | Methods and compositions for measuring Wnt activation and for treating Wnt-related cancers |
| DE102008019838A1 (de) | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| JP5369173B2 (ja) | 2008-04-22 | 2013-12-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キノリン若しくはイソキノリン置換ｐ２ｘ７アンタゴニスト |
| AR074199A1 (es) | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
| JP2012519661A (ja) | 2009-03-06 | 2012-08-30 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス性複素環化合物 |
| NZ617779A (en) | 2009-03-18 | 2015-08-28 | Resverlogix Corp | Novel anti-inflammatory agents |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| CN102666540A (zh) | 2009-10-13 | 2012-09-12 | Msd欧斯股份有限公司 | 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物 |
| JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
| CN102947274A (zh) | 2010-06-17 | 2013-02-27 | 诺瓦提斯公司 | 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物 |
| US9181266B2 (en) | 2011-07-13 | 2015-11-10 | Novartis Ag | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
| CA2841932A1 (en) | 2011-07-13 | 2013-01-17 | Novartis Ag | 4 - piperidinyl compounds for use as tankyrase inhibitors |
| EP2788328B1 (en) | 2011-11-25 | 2018-01-31 | Nerviano Medical Sciences S.r.l. | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
| KR101716012B1 (ko) | 2011-12-31 | 2017-03-13 | 베이진 엘티디 | Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 다이하이드로다이아제피노카르바졸론 |
| KR101684039B1 (ko) | 2011-12-31 | 2016-12-07 | 베이진 엘티디 | Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 피리도프탈라지논 |
| CN104080773B (zh) | 2012-01-28 | 2016-12-28 | 默克专利股份公司 | 氮杂环化合物 |
| WO2013116182A1 (en) | 2012-01-31 | 2013-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as inhibitors of leukotriene production |
| US9339503B2 (en) | 2012-02-09 | 2016-05-17 | Merck Patent Gmbh | Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors |
| EP2822944A1 (en) | 2012-03-05 | 2015-01-14 | Amgen, Inc. | Oxazolidinone compounds and derivatives thereof |
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| HRP20160908T1 (hr) | 2012-03-28 | 2016-09-23 | Merck Patent Gmbh | Biciklički derivati pirazinona |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| SG11201406997WA (en) | 2012-05-04 | 2014-11-27 | Merck Patent Gmbh | Pyrrolotriazinone derivatives |
| WO2013177349A2 (en) | 2012-05-25 | 2013-11-28 | Glaxosmithkline Llc | Quinazolinediones as tankyrase inhibitors |
| BR112014030416A2 (pt) | 2012-06-07 | 2017-06-27 | Hoffmann La Roche | composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção. |
| CA2874546A1 (en) | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase |
| CA2870062A1 (en) | 2012-06-20 | 2013-12-27 | F.Hoffmann-La Roche Ag | Pyrrolopyrazone inhibitors of tankyrase |
| HK1201066A1 (en) | 2012-06-20 | 2015-08-21 | 霍夫曼-拉罗奇有限公司 | Pyranopyridone inhibitors of tankyrase |
| CN104507912B (zh) | 2012-08-08 | 2016-09-28 | 默克专利股份公司 | (氮杂-)异喹啉酮衍生物 |
| EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| AR092211A1 (es) | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
| MX362855B (es) | 2012-09-26 | 2019-02-20 | Merck Patent Gmbh | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
-
2013
- 2013-03-07 RU RU2014138194A patent/RU2696572C2/ru not_active Application Discontinuation
- 2013-03-07 IN IN1875MUN2014 patent/IN2014MN01875A/en unknown
- 2013-03-07 WO PCT/GB2013/050561 patent/WO2013132253A1/en not_active Ceased
- 2013-03-07 MX MX2014010509A patent/MX346147B/es active IP Right Grant
- 2013-03-07 CN CN201380023162.0A patent/CN104302358B/zh not_active Expired - Fee Related
- 2013-03-07 US US14/381,712 patent/US9193689B2/en not_active Expired - Fee Related
- 2013-03-07 EP EP13709994.1A patent/EP2822656B1/en active Active
- 2013-03-07 JP JP2014560442A patent/JP6082409B2/ja not_active Expired - Fee Related
- 2013-03-07 KR KR1020147026143A patent/KR102104144B1/ko not_active Expired - Fee Related
- 2013-03-07 ES ES13709994.1T patent/ES2611504T3/es active Active
- 2013-03-07 DK DK13709994.1T patent/DK2822656T3/en active
- 2013-03-07 AU AU2013229229A patent/AU2013229229B2/en not_active Ceased
- 2013-03-07 CA CA2865511A patent/CA2865511A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049555A1 (en) | 2005-08-24 | 2007-03-01 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104302358A (zh) | 2015-01-21 |
| IN2014MN01875A (enExample) | 2015-07-03 |
| ES2611504T3 (es) | 2017-05-09 |
| JP6082409B2 (ja) | 2017-02-15 |
| CN104302358B (zh) | 2017-12-05 |
| US20150099732A1 (en) | 2015-04-09 |
| MX346147B (es) | 2017-03-09 |
| US9193689B2 (en) | 2015-11-24 |
| JP2015512885A (ja) | 2015-04-30 |
| EP2822656B1 (en) | 2016-10-19 |
| AU2013229229B2 (en) | 2017-10-19 |
| WO2013132253A1 (en) | 2013-09-12 |
| RU2696572C2 (ru) | 2019-08-05 |
| EP2822656A1 (en) | 2015-01-14 |
| MX2014010509A (es) | 2014-10-14 |
| CA2865511A1 (en) | 2013-09-12 |
| AU2013229229A1 (en) | 2014-09-25 |
| DK2822656T3 (en) | 2017-01-30 |
| KR20150001734A (ko) | 2015-01-06 |
| RU2014138194A (ru) | 2016-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2822656B1 (en) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | |
| EP3044221B1 (en) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | |
| EP2288601B1 (en) | Bicyclylaryl-aryl-amine compounds and their use | |
| EP2227460B1 (en) | Therapeutic oxy-phenyl-aryl compounds and their use | |
| EP2118076B1 (en) | Quinoxaline compounds and use thereof | |
| EP3189048B1 (en) | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors | |
| KR20220054293A (ko) | Isoqc 및/또는 qc 효소의 억제제로서 n-치환된-3,4-(융합된 5-환)-5-페닐-피롤리딘-2-온 화합물 | |
| BRPI0616799A2 (pt) | derivado de piridina e derivado de pirimidina (3), uso dos mesmos na preparação de composição farmacêutica, e composição farmacêutica, inibidor contra receptor de fator de crescimento de hepatócito, inibidor de angiogênese, agente antitumor e inibidor contra metástase de cáncer compreendendo os referidos compostos | |
| EA019966B1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| AU2007245496A1 (en) | Amino-ethyl-amino-aryl (AEAA) compounds and their use | |
| JP2015524826A (ja) | Ｖｅｇｆｒ３阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20230418 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20230418 |